Home › Compare › MHIVF vs ABBV
MHIVF yields 2500.00% · ABBV yields 3.06%● Live data
📍 MHIVF pulled ahead of the other in Year 1
Combined, MHIVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MHIVF + ABBV for your $10,000?
Invesque Inc. operates as a health care real estate investment company. Its portfolio includes investments in independent living, assisted living, memory care, skilled nursing, transitional care, and medical office properties. As of March 11, 2022, the company owned a portfolio of 88 properties, including 60 assisted living and memory care facilities, 12 skilled nursing facilities, 10 transitional care properties, and 4 medical office buildings in the United States; and 15 properties comprised 11 medical office buildings, and 4 seniors housing and care facilities in Canada. It also includes investments in owner occupied seniors housing properties, which comprise the ownership of real estate properties, as well as provides management services. The company was formerly known as Mainstreet Health Investments Inc. and changed its name to Invesque Inc. in January 2018. Invesque Inc. was incorporated in 2007 and is headquartered in Toronto, Canada.
Full MHIVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.